Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy
Authors:
- Maria MassaroMMMaria Massaro
- Davide FranceschiniDFDavide Franceschini
- Ruggero SpotoRSRuggero Spoto
- Luca DominiciLDLuca Dominici
- Ciro FranzeseCFCiro Franzese
- Davide BaldacciniDBDavide Baldaccini
- Beatrice MariniBMBeatrice Marini
- Luciana di CristinaLCLuciana di Cristina
- Marco A. MarzoMMMarco A. Marzo
- Lorenzo Lo FaroLFLorenzo Lo Faro
- Lucia PaganiniLPLucia Paganini
- Giacomo ReggioriGRGiacomo Reggiori
Open Access
- 12 July 2022
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 29 (7) , 4893-4901
Abstract
Background: This study evaluated the outcome, toxicity and predictive factors in patients unfit for concurrent chemo-radiotherapy (CT-RT) treated with hypofractionated sequential CT-RT or exclusive radiotherapy (RT) for locally advanced non-small cell lung cancer (LA-NSCLC). Methods: We included patients affected by LA-NSCLC (stage IIA-IVA) treated with a total dose of 50–60 Gy in 20 fractions. The primary outcomes were local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS). Univariate analysis was used to correlate outcomes with prognostic factors. Results: Between 2011 and 2019, 210 patients were treated, 113 (53.8%) with sequential CT-RT and 97 (46.2%) with exclusive RT. After a median follow-up of 15.3 months, 74 patients (35.2%) had a local progression and 133 (63.3%) had a distant progression. The one-, two- and five-year LC were 73.6%, 55.3% and 47.9%, respectively. At the time of analysis, 167 patients (79.5%) died. The one-, two- and five-year OS were 64.7%, 36% and 20%, respectively. PTV volume correlated with PFS (p = 0.001) and LC (p = 0.005). Acute and late toxicity occurred in 82% and 26% of patients. Conclusions: Albeit with the known limitations of a retrospective and heterogeneous study, our work shows that hypofractionated sequential CT-RT or exclusive RT offer a good local control and toxicity profile and a promising survival rate in LA-NSCLC patients unfit for the concurrent CT-RT scheme.Keywords
This publication has 18 references indexed in Scilit:
- Radical-Intent Hypofractionated Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer: A Systematic Review of the LiteratureClinical Lung Cancer, 2015
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 studyThe Lancet Oncology, 2015
- Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' dataThe Lancet Oncology, 2013
- Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-AnalysisJournal of Clinical Oncology, 2012
- Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung CarcinomaJournal of Thoracic Oncology, 2012
- Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With Chemoradiation: An Analysis of the Radiation Therapy Oncology GroupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non–small-cell lung cancer: Long-term results of a radiation dose escalation studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Improved local control with higher doses of radiation in large-volume stage III non–small-cell lung cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- A new approach to dose escalation in non–small-cell lung cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001